Media.Player

Bax Degradation Assay for Tumor Survival and Progression

Detailed Technology Description

None

Supplementary Information

Inventor: Dou, Ping | Li, Benyi
Priority Number: US6692927B2
IPC Current: A61K003817 | G01N0033574 | G01N003368
US Class: 43500723 | 435004 | 43500721 | 43500792 | 436008 | 436063 | 436064 | 436086 | 436164 | 436174 | 530300 | 530350 | 530386 | 5303871 | 5303877
Assignee Applicant: University of South Florida,Tampa
Title: Bax degradation involvement in tumor survival and progression
Usefulness: Bax degradation involvement in tumor survival and progression
Summary: For diagnosis, prognosis, prevention and treatment of cancer using determinations of Bax degradation levels. For determining or predicting tumor aggressiveness, for screening for Bax degradation inhibitors, and for determining the efficacy of protease inhibitors to prevent Bax degradation. Levels of Bax degradation activity also predict response of tumor cells to proteasome inhibitors and other anticancer drugs, or determine the efficacy of prospective chemotherapeutic agents and/or radiation therapy for treating cancer.
Novelty: Determining Bax degradation activity in patient sample, useful in cancer diagnosis, prognosis, prevention/treatment, comprises e.g. incubating labeled Bax protein with protein extract from sample, and detecting signal from labeled protein

Industry

Disease Diagnostic/Treatment

Sub Category

Cancer/Tumor

*Abstract

Researchers at the University of South Florida have developed a simple method to measure degradation of the Bax protein in a tumor sample. Information generated by this assay enables the user to investigate the mechanism of tumor survival, determine tumor grade, or screen for anti-cancer agents.Our investigatorsΓÇÖ method has multiple applications. Clinicians are able to determine whether tumor cells are surviving because of decreased Bax. The Bax degradation rate can help predict the most effective treatment for a tumor. Similarly, this assay is ideal for drug discovery programs screening for anti-canceragents. In addition, the rate of Bax degradation has been correlated in literature to determining tumor grade, and could be developed as a clinical predictive tumormarker.

Country/Region

USA